PATENT CLAIM ANALYSIS

Application Number: 16221274
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "300000"]

Abstract:
The invention relates to compounds of formula (I): wherein Q, A 1 , A 2 , A 3 , A 5 , A 6 , A 7 , A 8 , R 4a , R 4b  and R 5  are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Claim (Index 32):
The method of  claim 31 , wherein the inflammatory condition is selected from the group consisting of lupus, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), rhinitis, multiple sclerosis, inflammatory bowel disease (IBD), arthritis, rheumatoid arthritis, dermatitis, endometriosis and transplant rejection.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 98.0
- Lexical Diversity: 1.59184
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16220963', '15314938', '15026250', '14378975', '15904143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7831770602733537
- 35 USC 102 Novelty (BERT): 0.5639283949664375
- Combined Prediction Score: 0.7612521937426621
- Mean Citation Score: 329.27391
- Max Citation Score: 485.14618
- Similarity Product: 299.00691979969736

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test